Seagen reports fourth quarter and full year 2020 financial results

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today reported financial results for the fourth quarter and year ended december 31, 2020. the company also highlighted adcetris® (brentuximab vedotin), padcev® (enfortumab vedotin-ejfv) and tukysa® (tucatinib) commercial and development accomplishments, as well as progress with its lead pipeline programs to treat cancer. “in 2020, we generated record product revenues of more than $1 billion driven by successful launches of padcev and tu
SGEN Ratings Summary
SGEN Quant Ranking